The Topography of Metabolic Deficits in Posterior Cortical Atrophy (the Visual Variant of Alzheimers Disease) with FDG-PET
JNNP 74:1521-1529, Nestor,P.J.,et al, 2003
Plasma Homocysteine as a Risk Factor for Dementia and Alzheimer's Disease
NEJM 346:476-483, 466, Seshadri,S.,et al, 2002
Epilepsy Presenting as AD: Neuroimaging, Electroclinical Features, and Response to Treatment
Neurol 58:298-301, Hogh,P.,et al, 2002
Functional Deficits in Patients with Mild Cognitive Impairment
Neurol 58:758-764, Tabert,M.H.,et al, 2002
Alzheimer Disease
JAMA 287:2335-2338, Cummings,J.L. &Cole,G., 2002
Utility of Clinical Criteria in Differentiating Frontotemporal Lobar Degeneration (FTLD) From AD
Neurol 58:1608-1615, Rosen,H.J.,et al, 2002
Natural History of Mild Cognitive Impairment in Older Persons
Neurol 59:198-205, Bennett,D.A.,et al, 2002
Potentially Reversible Conditions in 1000 Consecutive Memory Clinic Patients
JNNP 73:390-394, Hejl,A.,et al, 2002
Reduced Incidence of AD with NSAID But Not H2 Receptor Antagonists
Neurol 59:880-886, Zandi,P.P.,et al, 2002
Prevalence of Neuropsychiatric Symptoms in Dementia and Mild Cognitive Impairment
JAMA 288:1475-1483, Lyketsos,C.G.,et al, 2002
Hormone Replacement Therapy and Incidence of Alzheimer Disease in Older Women
JAMA 288:2123-2129,2170, Zandi,P.P.,et al, 2002
Incidence and Outcome of Mild Cognitive Impairment in a Population-Based Prospective Cohort
Neurol 59;1594-1599, Larrieu,S.,et al, 2002
Mild Cognitive Impairment in Older People
Lancet 360:1963-1965, Burns,A., &Zaudig,M., 2002
CSF Detection of the 14-3-3 Protein in Unselected Patients with Dementia
Neurol 56:1528-1533, Burkhard,P.R.,et al, 2001
Stem-Cell Research: Drawing the Line
Lancet 358:163,217, Greenberg,D.S., 2001
Drugs for Alzheimer's Disease
BMJ 323:123-124, O'Brien,J.T . &Ballard,C.G., 2001
Galantamine (Reminyl) for Alzheimer's Disease
Medical Letter 43:53-54, , 2001
High-Dose Estradiol Improves Cognition for Women with AD, Results of a Randomized Study
Neurol 57:605-612, Asthana,S.,et al, 2001
A 24-Week, Randomized, Double-Blind Study of Donepezil in Moderate to Severe Alzheimer's Disease
Neurol 57:613-620, Feldman,H.,et al, 2001
Positron Emission Tomography in Evaluation of Dementia
JAMA 286:2120-2127,2194, Silverman,D.H.S.,et al, 2001
Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
NEJM 345:1515-1521,1567, in 'T Veld,B.A.,et al, 2001
Current Concepts in Mild Cognitive Impairment
Arch Neurol 58:1985-1992, Petersen,R.C.,et al, 2001
Influence of Leisure Activity on the Incidence of Alzheimer's Disease
Neurol 57:2236-2242, Scarmeas,N.,et al, 2001
Pathological Correlates of Late-Onset Dementia in a Multicentre, Community-based Population in England and Wales
Lancet 357:169-175, Neuroapthology Group of the Medical Research Counc, 2001
Effect of Donepezil on Brain Acetylcholineserase Activity in Patients with AD Measured by PET
Neurol 56:408-410, Shinotoh,H.,et al, 2001
Use of Specialized Coagulation Testing in the Evaluation of Patients with Acute Ischemic Stroke
Neurol 56:624-627, Bushnell,C.,et al, 2001
Magnetic Resonance Spectroscopy in AD
Neurol 56:592-598, Valenzuela,M.J.,et al, 2001
Age-Related Memory Decline
Arch Neurol 58:360-364, Small,S.A., 2001
Evaluation of CSf-tau and CSF-AB42 as Diagnostic Markers for Alzheimer Disease in Clinical Practice
Arch Neurol 58:373-379,349, Andreasen,N.,et al, 2001
Hormone Replacement Therapy and Cognition
JAMA 285:1489-1499, LeBlanc,E.S.,et al, 2001
Early Detection of Dementia: Mild Cognitive Impairment (an Evidence-based Review)
Neurol 56:1133-1142, 1131, Petersen,R.C.,et al, 2001
A Reevaluation of the Duration of Survival After the Onset of Dementia
NEJM 344:1111-1116, Wolfson,C.,et al, 2001
The Effect of Brain Atrophy on Cerebral Hypometabolism in the Visual Variant of Alzheimer Disease
Arch Neurol 58:480-486, Bokde,A.L.W.,et al, 2001
A 5-Month, Randomized, Placebo-controlled Trial of Galantamine in AD
Neurol 54:2269-2276, Tariot,P.N.,et al, 2000
Galantamine in AD
Neurol 54:2261-2268, Raskind,M.A.,et al, 2000
Donepezil Therapy in Clinical Practice, A Randomized Crossover Study
Arch Neurol 57:94-99, Greenberg,S.M.,et al, 2000
Might Olfactory Dysfunction be a Marker of Early Alzheimer's Disease?
Lancet 355:84-85, Burns,A., 2000
Estrogen for Alzheimer's Disease in Women, Randomized, Double-Blind, Placebo-Controlled Trial
Neurol 54:295-301, Henderson,V.W.,et al, 2000
An 80-Year-Old Man With Memory Loss
JAMA 283:1046-1053, Larson,E.B., 2000
Using Serial Registered Brain Magnetic Resonance Imaging to Measure Disease Progression in Alzheimer Disease
ArchNeurol 57:339-344, Fox,N.C.,et al, 2000
Diagnostic Accuracy of Dementia with Lewy Bodies
ArchNeurol 57:347-351, Hohl,U.,et al, 2000
Estrogen Replacement Therapy for Treatment of Mild to Moderate Alzheimer Disease
JAMA 283:1007-1015,1055, Mulnar,R.A.,et al, 2000
Progression of Parkinsonian Signs in Alzheimer's Disease
Neurol 54:1284-1289, Wilson,R.S.,et al, 2000
Practice Parameter: Risk of Driving and Alzheimer's Disease (An Evidence-Based Review)
Neurol 54:2205-2211, Dubinsky,R.M.,et al, 2000
The Preclinical Phase of Alzheimer Disease
Arch Neurol 57:808-813, Elias,M.F.,et al, 2000
Reduced Prevalence of AD in Users of NSAIDs and H2 Receptor Antagonists
Neurol 54:2066-2071, Anthony,J.C.,et al, 2000
Smoking and Dementia in Male British Doctors: Prospective Study
BMJ 320:1097-1102,1087, Doll,R.,et al, 2000
Variability of the Mini-Mental State Examination in Dementia
Neurol 54:1538-1539, Doraiswamy,P.M.&Kaiser,L., 2000
Survival in End-Stage Dementia Following Acute Illness
JAMA 284: 47-52, 87, Morrison,R.S. & Siu,A.L., 2000
Treating Nondementia Illnesses in Patients With Dementia
JAMA 283:3230-3235, Brauner,D.J. et al, 2000